Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KI 8110

Known as: KI-8110, Uridine, 5'-O-(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-alpha-neuraminosyl)-5-fluoro-2',3'-O-(1-methylethylidene)- 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

GlycosidesUridine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Desialylation of metastatic human colorectal carcinoma cells facilitates binding to Kupffer cells
Cell surface hypersialylation of human colorectal carcinoma (HCRC) cells correlates with increased metastatic potential after… Expand
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
1993
1993
Inhibition of CMP-sialic acid transport in human liver and colorectal cancer cell lines by a sialic acid nucleoside conjugate (KI-8110).
The sialic acid nucleoside conjugate KI-8110 has been shown to inhibit the formation of hepatic metastases from human colorectal… Expand
Highly Cited
1992
Highly Cited
1992
Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases.
Sialyltransferase activity (EC 2.4.99.6) was measured in the microsomal fraction of colorectal cancer cell lines using an assay… Expand
1990
1990
Inhibition of sialic acid incorporation prevents hepatic metastases.
It has been hypothesized that the metastatic capacity of tumors may be correlated with hypersialylation of the cell surface. We… Expand
1988
1988
Possible mechanism of inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: nucleoside conjugate.
As described previously (I. Kijima-Suda et al., Cancer Res., 46: 858-862, 1986), a sialyltransferase inhibitor, 5-fluoro-2',3… Expand
  • table 1
  • table 4
  • figure 1
  • table 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE